Reducing peripheral intravenous cannula failure in neonates
Effect of a splint and intravenous protection device on peripheral intravenous cannula failure in neonates.
Monash Health
100 participants
Jul 31, 2019
Interventional
Conditions
Summary
Peripheral IV cannulation is one of the most frequently performed invasive procedures in the hospital setting, and an essential means of providing hydration, nutrition and medication to admitted patients, including neonates . The insertion, monitoring and maintenance of these devices, to prevent complications, are an important component of neonatal nursing care. The most common complications of PIVC use include extravasation, infiltration, occlusion, infection, and phlebitis - accounting for the failure and removal of 95% of PIVCs. Although these complications are usually minor, some neonates may experience serious, or even life-threatening sequelae, with the potential for long-term functional difficulties, significant scarring, and psychological effects. The current failure rate of PIVC in the neonatal population is estimated at around 60%, however the optimal securement method of a PIVC has not been well established. We have designed a randomised controlled trial to assess whether using a specifically designed splint and protection device may be useful to prevent PIVC failure as compared to standard splinting and securement in the neonatal population. Our hypothesis is that the specifically designed splint and protection device will significantly decrease PIVC failure as compared to standard splinting and securement in the neonatal population.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A randomised controlled trial to assess whether using a specifically designed splint and protection device may be useful to prevent (peripheral intravenous cannula) PIVC failure as compared to standard splinting and securement in the neonatal population. Specific splint and IV protective product (I.V. house, Inc, MO, USA) – 939S-Ultra TLC Foam Padded Wrist Splint with Two Straps and Velcro Closure, or 949XS TLC Foam Padded Foot Splint with Two Straps and Velcro Closure; in conjunction with the I.V. House 330 Series I.V. House UltraDressing IV site protector. Intervention will be administered by any health professional inserting and/or securing the PIVC. The intervention will continue for the life of that PIVC which may be minutes, hours or days till the PIVC is removed. This is a likely to be less than 7 days in most cases. Adherence to intervention will be ensured by observation and cannula log maintained by bedside nurses.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12619000798167